乳腺癌的发病机制及临床治疗的研究进展
摘要
基因突变、激素水平及不良生活方式等多方面，剖析其发病根源。同时，全面阐述乳腺癌治疗临床研究新进展，涉及手术、
放疗、化疗及内分泌治疗等，旨在为临床治疗决策提供科学依据，助力改善患者预后，延长生存期，提高生活质量。
关键词
全文:
PDF参考
[1] 全球疾病负担癌症协作组 . 1990 年至 2015 年全球、
区域和国家 32 种癌症组的癌症发病率、死亡率、寿命损失
年数、残疾年数和残疾调整生命年数 . JAMA Oncol. 2017 年
4 月 1 日 ;3(4):524-548.
[2] Möller S, Mucci LA, Harris JR, Scheike T, Holst K,
Halekoh U, Adami HO, Czene K, Christensen K, Holm NV,
Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB. The Heritability of
Breast Cancer among Women in the Nordic Twin Study of Cancer.
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50. doi:
10.1158/1055-9965.EPI-15-0913.
[3] Sampson JN, Wheeler WA, Yeager M, et al. Analysis
of Heritability and Shared Heritability Based on Genome-Wide
Association Studies for Thirteen Cancer Types. J Natl Cancer Inst.
2015 Oct 12;107(12):djv279. doi: 10.1093/jnci/djv279. Erratum
in: J Natl Cancer Inst. 2016 Apr;108(4).
[4] Severi G, Southey MC, English DR, et al. Epigenome-wide
methylation in DNA from peripheral blood as a marker of risk for
breast cancer. Breast Cancer Res Treat. 2014 Dec;148(3):665-73.
[5] Yang Y, Wu L, Shu XO, et al. Genetically Predicted
Levels of DNA Methylation Biomarkers and Breast Cancer Risk:
Data From 228 951 Women of European Descent. J Natl Cancer
Inst. 2020 Mar 1;112(3):295-304.
[6] Allott EH, Hursting SD. Obesity and cancer: mechanistic
insights from transdisciplinary studies. Endocr Relat Cancer. 2015
Dec;22(6):R365-86.
[7] Zeitzer JM, Nouriani B, Rissling MB, Sledge GW, Kaplan
KA, Aasly L, Palesh O, Jo B, Neri E, Dhabhar FS, Spiegel D.
Aberrant nocturnal cortisol and disease progression in women with
breast cancer. Breast Cancer Res Treat. 2016 Jul;158(1):43-50.
[8] 乳腺癌激素因素协作组 . 绝经后激素治疗的类型和
时机与乳腺癌风险：全球流行病学证据的个体参与者荟萃分
析 . Lancet. 2019 年 9 月 28 日 ;394(10204):1159-1168.
[9] 北美更年期学会 . 北美更年期学会 2012 年激素治疗
立场声明 . 更年期 . 2012 年 3 月 ;19(3):257-71.
[10] Cottet V, Touvier M, Fournier A, Touillaud MS, Lafay L,
Clavel-Chapelon F, Boutron-Ruault MC. Postmenopausal breast
cancer risk and dietary patterns in the E3N-EPIC prospective
cohort study. Am J Epidemiol. 2009 Nov 15;170(10):1257-67.
[11] Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM,
Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M,
Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz
E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing
H, Martín M; GEICAM researchers. Spanish Mediterranean diet
and other dietary patterns and breast cancer risk: case-control
EpiGEICAM study. Br J Cancer. 2014 Sep 23;111(7):1454-62.
[12] Hirko KA, Willett WC, Hankinson SE, Rosner BA, Beck
AH, Tamimi RM, Eliassen AH. Healthy dietary patterns and risk
of breast cancer by molecular subtype. Breast Cancer Res Treat.
2016 Feb;155(3):579-88.
[13] McTiernan A, Friedenreich CM, Katzmarzyk PT,
Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B,
Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy
KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY
COMMITTEE*. Physical Activity in Cancer Prevention and
Survival: A Systematic Review. Med Sci Sports Exerc. 2019
Jun;51(6):1252-1261.
[14] Ibrahim EM, Al-Homaidh A. Physical activity and
survival after breast cancer diagnosis: meta-analysis of published
studies. Med Oncol. 2011 Sep;28(3):753-65.
[15] Stick LB, Yu J, Maraldo MV, Aznar MC, Pedersen AN,
Bentzen SM, Vogelius IR. Joint Estimation of Cardiac Toxicity
and Recurrence Risks After Comprehensive Nodal Photon Versus
Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys.
2017 Mar 15;97(4):754-761.
[16] Tanaka S, Iwamoto M, Kimura K, Matsunami N,
Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto
D, Tsubota Y, Kobayashi T, Uchiyama K. Phase II Study of
Neoadjuvant Anthracycline-Based Regimens Combined With
Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for
Human Epidermal Growth Factor Receptor 2-Positive Operable
Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):191-6.
[17] Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr,
Jeong JH, Tan-Chiu E, Fisher B, Wolmark N. Prognosis after
ipsilateral breast tumor recurrence and locoregional recurrences
in five National Surgical Adjuvant Breast and Bowel Project node-
positive adjuvant breast cancer trials. J Clin Oncol. 2006 May
1;24(13):2028-37.
[18] Donker M, van Tienhoven G, Straver ME, Meijnen P, van
de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl
JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen
GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T,
Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi
Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J,
Rutgers EJ. Radiotherapy or surgery of the axilla after a positive
sentinel node in breast cancer (EORTC 10981-22023 AMAROS):
a randomised, multicentre, open-label, phase 3 non-inferiority
trial. Lancet Oncol. 2014 Nov;15(12):1303-10.
[19] Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D,
Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M,
Ingle J, Peto R. Relevance of breast cancer hormone receptors
and other factors to the efficacy of adjuvant tamoxifen: patient-
level meta-analysis of randomised trials. Lancet. 2011 Aug
27;378(9793):771-84.
[20] Bidard FC, Kaklamani VG, Neven P, Streich G, Montero
AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden
KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S,
Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P,
Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG,
Bardia A. Elacestrant (oral selective estrogen receptor degrader)
Versus Standard Endocrine Therapy for Estrogen Receptor-
Positive, Human Epidermal Growth Factor Receptor 2-Negative
Advanced Breast Cancer: Results From the Randomized Phase III
EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。